WeightWatchers’ CEO on diet drugs: ‘The key is re-owning weight’
Tara Comonte is putting fat jabs at centre of a plan to steer company through bankruptcy protection
Related reading
Can WeightWatchers stay relevant when everyone is on diet drugs?
GLP-1 medications could be the group’s death knell — or grant it a new lease on life
Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history
Off the Scales — the impact of weight-loss jabs, from our bodies to the pharma…
Focusing on Novo Nordisk, Aimee Donnellan’s book ranges across R&D, patents, medical effects and the stigma attached to obesity
Battle for weight-loss supremacy shifts from jabs to pills
Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly
Hims & Hers abandons copycat weight-loss drug in face of FDA probe
Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy
Weight-loss drugs are bringing a new commercial reality
The reinforcing feedback loop that has long powered the food industry is being chemically switched off